Assistant Professor and CPRIT Scholar in Cancer Research Department of Bioengineering at Rice University. Co-founder of Sigilon Therapeutics.
Dr. Veiseh worked to develop a bioartificial pancreas for the treatment of patients afflicted with type 1 diabetes. Dr. Veiseh developed a high-throughput pipeline for the synthesis and evaluation of material formulations that are able to resist foreign body reactions. These formulations were used to develop novel biomaterials for enhanced biocompatibility.
He has authored or co-authored more than 50 peer-reviewed publications and is an inventor on 20 pending or awarded patents.